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Available online 12 November 2016Background: Disseminated or fatal Zika virus (ZIKV) infections were reported in immunosuppressed patients.
Existing interferon-signaling/receptor-deﬁcient mouse models may not be suitable for evaluating treatment ef-
fects of recombinant interferons.
Methods:We developed a novel mousemodel for ZIKV infection by immunosuppressing BALB/cmicewith dexa-
methasone.
Results: Dexamethasone-immunosuppressed male mice (6–8 weeks) developed disseminated infection as evi-
denced by the detection of ZIKV-NS1 protein expression and high viral loads in multiple organs. They had
≥10% weight loss and high clinical scores soon after dexamethasone withdrawal (10 dpi), which warranted eu-
thanasia at 12 dpi. Viral loads in blood and most tissues at 5 dpi were signiﬁcantly higher than those at 12 dpi
(P b 0.05). Histological examination revealed prominent inﬂammatory inﬁltrates in multiple organs, and
CD45+and CD8+ inﬂammatory cells were seen in the testis. Theseﬁndings suggested that clinical deterioration
occurred during viral clearance by host immune response. Type I interferon treatments improved clinical out-
come of mice (100% vs 0% survival).
Conclusions: Besides virus dissemination, inﬂammation of various tissues, especially orchitis, may be potential
complications of ZIKV infection with signiﬁcant implications on disease transmission andmale fertility. Interfer-
on treatment should be considered in patients at high risks for ZIKV-associated complicationswhen the potential
beneﬁts outweigh the side effects of treatment.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Zika virus (ZIKV) is an emerging ﬂavivirus that has been largely
neglected for N60 years after its discovery due to its restricted geo-
graphical distribution and its presumed low clinical signiﬁcance (Chan
et al., 2016a). Since 2007, large-scale outbreaks of ZIKV infection have
occurred in the Paciﬁc islands, Latin America, and most recently, USA
and Southeast Asia (Duffy et al., 2009; Musso and Gubler, 2016; Zhu
et al., 2016). As of 27 October 2016, N70 countries/territories havethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Health Organization. Zika situation report. October 27, 2016). In addi-
tion to mosquito-borne transmission, sexual and transplacental trans-
missions of ZIKV have also been reported (Chan et al., 2016a; Musso
et al., 2015a; Foy et al., 2011; Calvet et al., 2016). These non-vector-
borne transmission routes render the control of the continuing epidem-
ic more complicated.
ZIKV was not considered as an important human pathogen in the
past as most infected adult patients were asymptomatic or developed
a self-limiting acute febrile illness which resolved within 1–2 weeks
(Chan et al., 2016a; Duffy et al., 2009). However, it has been recently
recognized that infected mothers may transmit the virus transplacen-
tally to developing fetuses, leading to congenital malformations, includ-
ing microcephaly, cerebral malformations, ophthalmological and
hearing defects, and arthrogryposis (Chan et al., 2016a; Mlakar et al.,
2016; de Paula et al., 2016; Leal et al., 2016). Some infected adults
may also develop severe neurological complications, such as Guillain-
Barré syndrome, meningoencephalitis, and myelitis (Cao-Lormeau et
al., 2016; Carteaux et al., 2016; Mecharles et al., 2016). Moreover,
ZIKV-related fatalities have been increasingly recognized. Most of the
patients with fatal infection had underlying medical conditions and
some were markedly immunosuppressed, including a patient with sys-
temic lupus erythematosus and rheumatoid arthritis who was on corti-
costeroid therapy and died of disseminated infection with detectable
ZIKV RNA in blood, brain, spleen, liver, kidney, lung, and heart obtained
at postmortem examination (Pan American Health Organization/World
Health Oganization (PAHO/WHO), 2015; Sarmiento-Ospina et al., 2016;
Arzuza-Ortega et al., 2016).
A number of animal models have been developed for studying the
pathogenesis and evaluating countermeasures for ZIKV infection.
Rhesus macaques with subcutaneous ZIKV inoculation develop mild
clinical signs that resemble the self-limiting illness in most infected im-
munocompetent adults (Dudley et al., 2016). This non-human primate
model provides a robust platform for the evaluation of vaccines and
host immune response (Abbink et al., 2016). However, the mild clinical
disease in these primates is suboptimal for antiviral treatment evalua-
tion. Moreover, expertise and facilities for working with non-human
primates are not available in most research laboratories. Wild-type
adult BALB/c mice are not susceptible to intraperitoneal ZIKV inocula-
tion (Dick, 1952). Suckling and young mice with intracerebral ZIKV in-
oculation develop disease that is localized to the central nervous
system (Dick, 1952; Way et al., 1976; Weinbren and Williams, 1958;
Bell et al., 1971). Pregnant mice and fetal mice with partially intact
type I interferon signaling response (fetuses of female mice deﬁcienct
in type I interferon signaling response crossed to wild-type male
mice) were used to study pathogenesis in pregnancy and maternal-
fetal transmission, but these models are technically more demanding
(Miner et al., 2016; Cugola et al., 2016). Type I/II interferon-signaling-/
receptor-deﬁcient mice with intraperitoneal or subcutaneous ZIKV in-
oculation develop fatal, disseminated infection (Lazear et al., 2016;
Dowall et al., 2016; Aliota et al., 2016; Rossi et al., 2016). These models
are useful for the evaluation of countermeasures for ZIKV infection as
the protective effects of antivirals drugs and vaccines are more easily
observed in treated mice. However, such models have complete/near-
complete deﬁciency in interferon response and do not resemble the
real clinical situation in immunosuppressed humans. Moreover, these
mice are suboptimal for the study of host immune response and may
be too expensive for laboratories in resource-limited areas.
Because of these limitations and knowledge gaps, we developed and
characterized a more readily available mouse model which resembles
immunosuppressed hosts with disseminated infection. We showed
that these mice developed inﬂammation in multiple organs, including
the testes, which may have important implications on ZIKV's long-
term outcome and effects on fertility. We also utilized this novel animal
model to show that early treatment with clinically approved recombi-
nant type I interferons improved the clinical outcome of these mice.2. Methods
2.1. Virus Strain and Titration
A clinical isolate of ZIKV (Puerto Rico strain PRVABC59) was kindly
provided by Brandy Russell and Barbara Johnson, Centers for Disease
Control and Prevention, USA. The viruswas ampliﬁed by three addition-
al passages in Vero cells (ATCC) in minimum essential medium (MEM)
supplemented with 1% fetal calf serum and 100 units/ml penicillin plus
100 μg/ml streptomycin to make working stocks of the virus. For virus
titration, aliquots of ZIKV were applied on conﬂuent Vero cells in 96-
well plates for 50% tissue culture infectious dose (TCID50) assay as we
previously describedwith slightmodiﬁcations (Zhou et al., 2014). Brief-
ly, serial 10-fold dilutions of ZIKV were inoculated in a Vero cell mono-
layer in quadruplicate and cultured in penicillin/streptomycin-
supplemented MEM. The plates were observed for cytopathic effect
for 5 days. Viral titer was calculatedwith the Reed andMünch endpoint
method. One TCID50 was interpreted as the amount of virus that causes
cytopathic effect in 50% of inoculated wells.
2.2. Animal Model and Viral Challenge
Approval was obtained from the Committee on the Use of Live Ani-
mals in Teaching and Research of The University of Hong Kong. Male
and female BALB/c mice, 6–8 weeks old, were obtained from the Labo-
ratory Animal Unit of The University of Hong Kong. The mice were
kept in biosafety level-2 housing and given access to standard pellet
feed and water ad libitum. Virus inoculation experiments were per-
formed in a biosafety level-2 animal facility according to the standard
operatingprocedures approved by the Committee on theUse of Live An-
imals in Teaching and Research of The University of Hong Kong as we
described previously (Zhang et al., 2014). The mice were randomly di-
vided into 11 groups and given different regimens of virus inoculation,
dexamethasone, and recombinant interferon treatment (Table 1). Phos-
phate-buffered saline (PBS) was used to dilute the virus stocks to the
desired concentration, and inocula were back-titrated to verify the
dose given. On the day of virus inoculation, a dose of the virus equiva-
lent to 6 × 106 TCID50 (3.24 × 106 plaque forming units) in 200 μl of
PBS was inoculated via the intraperitoneal route into mice under keta-
mine (100mg/kg) and xylazine (10mg/kg) anesthesia. Mice in the neg-
ative-control groups (groups 5 to 8) were injected with the same
volume of PBS. Mice were monitored three times each day for clinical
signs of disease and a numerical score was assigned at each observation
as previously described (Dowall et al., 2016; Graham et al., 2015). Their
body weight and survival were monitored for 14 days post-inoculation
(dpi) or until euthanasia. Three mice in each group (except groups 7
and 8 which included mock-infected control mice without dexametha-
sone immunosuppression and group 9which included ZIKV-inoculated,
dexamethasone-immunosuppressed mice without dexamethasone
withdrawal)were sacriﬁced at 5 dpi for virological, histological, and im-
munohistochemistry analyses. The remaining mice were sacriﬁced at
14 dpi or euthanized when there was a 20% weight loss or 10% weight
loss with ≥1 clinical sign (Dowall et al., 2016). Samples of brain, testis/
epididymis (male), prostate (male), ovary/uterus (female), kidney, uri-
nary bladder, spleen, liver, pancreas, intestine, heart, lung, and salivary
gland were collected at necropsy. The specimens were separated into
two parts, one immediately ﬁxed in 10% PBS-buffered formalin, the
other immediately frozen at−80 °C until further experiments. Blood
samples were also collected for RNA extraction and real-time PCR
analysis.
2.3. Histopathology and Immunohistochemistry
Parafﬁn-embedded tissues were cut into 4–6 μm sections, mounted
on slides, and stained with hematoxylin and eosin (H&E) for light mi-
croscopy examination as we previously described (Zheng et al., 2008).
Table 1
Eleven groups of mice receiving different regimens of virus inoculation, dexamethasone, and antiviral treatment in this studya.
Group Gender Routes and inoculum of ZIKV
(0 dpi)
Dexamethasone Antiviral treatmentb Date of
sacriﬁce/euthanasia
1 M ip 6 × 106 TCID50 50 mg/kg q24h ip, from 3 days before to 9 dpi
inclusively
No 5 (n = 3) and 12
(n = 6) dpic
2 F ip 6 × 106 TCID50 50 mg/kg q24h ip, from 3 days before to 9 dpi
inclusively
No 5 (n = 3) and 14
(n = 6) dpi
3 M ip 6 × 106 TCID50 No No 5 (n = 3) and 14
(n = 6) dpi
4 F ip 6 × 106 TCID50 No No 5 (n = 3) and 14
(n = 6) dpi
5 M No 50 mg/kg q24h ip, from 3 days before to 9 dpi
inclusively
No 5 (n = 3) and 14
(n = 6) dpi
6 F No 50 mg/kg q24h ip, from 3 days before to 9dpi
inclusively
No 5 (n = 3) and 14
(n = 6) dpi
7 M No No No 14 (n = 6) dpi
8 F No No No 14 (n = 6) dpi
9 M ip 6 × 106 TCID50 50 mg/kg q24h ip, from 3 days before to 13 dpi
inclusively
No 14 (n = 6) dpi
10 M ip 6 × 106 TCID50 50 mg/kg q24h ip, from 3 days before to 9 dpi
inclusively
Pegylated IFN-α2b 1920 IU/dose q96h sc at 1,
5, and 9 dpi
5 (n = 3) and 14
(n = 8) dpi
11 M ip 6 × 106 TCID50 50 mg/kg q24h ip, from 3 days before to 9 dpi
inclusively
IFN-β1b 160,000 IU/dose q48h ip at 1, 3, 5, 7,
and 9 dpi
5 (n = 3) and 14
(n = 8) dpi
Abbreviations: dpi, days post-inoculation; F, female; IFN, interferon; ip, intraperitoneal; M, male; sc, subcutaneous.
a 6–8 week-old BALB/c mice were used in all the groups.
b The preparations of pegylated IFN-α2b and IFN-β1b used in this study were PegIntron (Merck & Co., Inc., Whitehouse Station, NJ, USA) and Betaferon (Bayer Schering Pharma AG,
Berlin, Germany), respectively.
c The mice in group 1 were euthanized at 12 dpi as they had ≥10% weight loss and ≥1 clinical symptom.
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rum against ZIKV-NS1 protein prepared aswe previously describedwas
used as primary antibody (Chan et al., 2016b). De-parafﬁnized and
rehydrated tissue sections were treated with Antigen Unmasking Solu-
tion according to manufacturer's instructions (Vector Laboratories Inc.,
Burlingame, CA, USA) and then stained with Mouse on Mouse Polymer
IHC kit (Abcam, Cambridge, United Kingdom). The primary antibody
mouse anti-ZIKV-NS1 antiserum (1:1000 dilution with 1% BSA/PBS)
was incubated at 4 °C overnight. This was followed by Mouse on
Mouse HRP polymer kit (Abcam) with horseradish peroxidase-conju-
gated secondary antibody for 15 min. Color development was per-
formed using 3,3′-diaminobenzidine (DAB) (Vector Laboratories,
Burlingame, CA, USA). For immunohistochemical staining of CD45 and
CD8, the sectionswere incubated at 4 °C for overnight with primary an-
tibody (rabbit anti-mouse CD45, or rat anti-mouse CD8α (Abcam) after
antigen unmasking and blocking. This was then followed by incubation
with biotin-conjugated goat anti-rabbit IgG or goat anti-rat IgG
(Calbiochem, Darmstadt, Germany) for 30 min at room temperature.
Streptavidin/peroxidase complex reagent (Vector Laboratories) was
then added and incubated at room temperature for 30min. Color devel-
opment was done with DAB (Vector Laboratories). All tissue sections
were examined microscopically by two pathologists in an operator-
blinded manner. Images were captured with Nikon80i imaging system
equipped with Spot-advance computer software.
2.4. Viral Load Studies
Total nucleic acid (TNA)was extracted from the blood and necropsied
tissues using EZ1 Virus Mini Kit v2.0 and QIAsymphony DSP Virus/Patho-
gen Mini Kit (QIAGEN, Hilden, Germany), respectively, as we previously
described (Zheng et al., 2008; Chan et al., 2016b; Chan et al., 2015a).
ZIKV envelope gene was measured by using QuantiNova Probe RT-PCR
Kit (QIAGEN) in LightCycler 96 Real-TimePCR System (RocheDiagnostics,
Basel, Switzerland). 5 μl of puriﬁed TNAwas ampliﬁed in a 20 μl-reaction
containing 10 μl of 2× QuantiNova Probe RT-PCR Master Mix, 0.2 μl QN
Probe RT-mix, 0.8 μM forward primer, 0.8 μM reverse primer, and
200 nM probe. Forward primer (5′-CGYTGCCCAACACAAGG-3′), reverse
primer (5′-CCACYAAYGTTCTTTTGCABACA-3′), and probe (5′-HEX-
AGCCTACCTTGAYAAGCARTCAGACACTC-IABkFQ-3′) targeting the ZIKVenvelope gene as we previously described were used (Chan et al.,
2016b). Reactions were incubated at 45 °C for 10 min, followed by 95 °C
for 5 min, and then thermal cycled for 50 cycles (95 °C for 5 s, 55 °C for
30 s). Internal control β-actin gene was measured by using QuantiNova
SYBR Green RT-PCR Kit (QIAGEN) in LightCycler 96 Real-Time PCR Sys-
tem. 5 μl of puriﬁed TNA was ampliﬁed in a 20 μl-reaction containing
10 μl of 2× QuantiNova SYBR Green RT-PCR Master Mix, 0.2 μl QN SYBR
Green RT-mix, 0.5 μM forward primer (5′-ACGGCCAGGTCATCACTATTG-
3′) and 0.5 μM reverse primer (5′-CAAGAAGGAAGGCTGGAAAAG-3′) for
the β-actin gene. Reactions were incubated at 50 °C for 10 min, followed
by 95 °C for 2 min, and then thermal cycled for 50 cycles (95 °C for 5 s,
60 °C for 10 s). A series of 10-fold dilutions equivalent to 1 × 102 to
1 × 106 copies/reaction mixture were prepared to generate standard
curves and run in parallel with the test samples.
2.5. Statistical Analysis
All data were analyzed with GraphPad Prism software (GraphPad
Software, Inc). Kaplan-Meier survival curves were analyzed by the log
rank test, and weight losses were compared using two-way ANOVA.
Student's t-testwas used to determine signiﬁcant differences in virus ti-
ters, and Tukey–Kramer post hoc tests were used to discern differences
among individual treatment groups as previously reported (Aliota et al.,
2016; Rossi et al., 2016). P-values b0.05 were considered statistically
signiﬁcant.
3. Results
3.1. Dexamethasone-immunosuppressed Mice Developed Disseminated
ZIKV Infection
To establish a novel mouse model for ZIKV infection, we compared
the clinical, histological, and virological ﬁndings of male (group 1) and
female (group 2) mice with dexamethasone immunosuppression and
ZIKV inoculation with those of the appropriate controls (groups 3 to
8) (Table 1). In terms of the clinical parameters, thedexamethasone-im-
munosuppressed mice developed mild (~5%) weight loss (Fig. 1A) and
nomortality at 5 dpi (Fig. 1B and C). Theweight losses of the dexameth-
asone-immunosuppressedmicewith ZIKV inoculation (groups 1 and 2)
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Fig. 1. Comparison between the clinical ﬁndings of the dexamethasone-immunosuppressed BALB/c mice with ZIKV inoculation and control mice. (A) Body weights, (B) clinical scores,
and (C) survival times and rates. Body weights of the mice were monitored for 14 days (survival mice) or until euthanasia. Total n = 6 per group. Results were combined from two
independent experiments. Clinical scores: normal = 0; rufﬂed fur = 2; lethargy, pinched, hunched, wasp waisted = 3; labored breathing, rapid breathing, inactive, neurological = 5;
and immobile = 10.
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including the ZIKV-inoculated mice without dexamethasone immuno-
suppression (groups 3 and 4) and mock-infected mice without dexa-
methasone immunosuppression (groups 7 and 8) starting at 1 dpi
(P b 0.05). Minimal histological changes and inﬂammatory inﬁltrates
were seen in the tissues of the male and female mice with dexametha-
sone immunosuppression and ZIKV inoculation (groups 1 and 2). On
the other hand, ZIKV-NS1 protein expressionwas detected by immuno-
histochemical staining in most tissues of these mice, but not in dexa-
methasone-immunosuppressed mice with mock infection (groups 5
and 6), suggesting that the viral protein expression was speciﬁc and
not related to dexamethasone effects (Fig. 2). The dexamethasone-im-
munosuppressed mice with ZIKV inoculation (groups 1 and 2) also
had high mean viral loads in blood and most tissues at 5 dpi, especially
in the testis/epididymis, ovary/uterus, prostate, spleen, and pancreas
(Figs. 3A and B and S1A and B). These ﬁndings at 5 dpi were suggestive
of disseminated but non-lethal ZIKV infection involving different organs
with minimal inﬂammatory response due to dexamethasone
immunosuppression.
3.2. Clinical Deterioration with Multi-organ Inﬂammatory Cell Inﬁltrates
Occurred in the Mice after Dexamethasone Withdrawal
To investigate the possible effects of immune reconstitution in
the dexamethasone-immunosuppressed mice, dexamethasone was
stopped after 9 dpi. This led to prominent weight loss and increased
symptoms in the dexamethasone-immunosuppressed mice (groups 1
and 2). The most prominent body weight loss was observed in the
malemicewith dexamethasone immunosuppression and ZIKV inocula-
tion (group 1), with all 6 mice having weight loss of ≥10% at 12 dpi
(Fig. 1A). All of the female mice with dexamethasone immunosuppres-
sion and ZIKV inoculation (group 2) also had progressive weight lossand 4/6 (66.7%) of them had ≥10% weight loss at 14 dpi. In contrast,
none of the mice with dexamethasone immunosuppression from
3 days before to 13 days post-infection (group 9) developed abrupt
weight loss between 10 dpi and 14 dpi (Fig. 1A). The weight loss of
mice in groups 1 and 2 became consistently more than those of their
comparators in the other control groups (groups 3 to 8), including
those in the dexamethasone-immunosuppressedmicewithmock infec-
tion (groups 5 and 6) since 10 dpi (P b 0.05). Together, these ﬁndings
suggested that the combination of immune reconstitution after dexa-
methasonewithdrawal and disseminated virus infectionwere responsi-
ble for the abrupt clinical deterioration. All of themice in groups 1 and 2
developed rapid breathing, lethargy, and/or rufﬂed fur since 11 dpi
(group 1) or 12 dpi (group 2), shortly after dexamethasone was
stopped(Fig. 1B). The reasons for the earlier onset of weight loss and
symptoms in themalemicewere not fully understood, but might be re-
lated to the higher cumulative dose of dexamethasone because of their
higher baseline body weights and/or possible effects of androgen on
virus replication (Tian et al., 2012). Based on the predeﬁned criteria,
all 6 (100%) male and 4/6 (66.7%) female mice were euthanized at
12 dpi and 14 dpi, respectively (Fig. 1C). Comparatively, all the mice in
the other control groups (groups 3 to 9) had either gained weight or
had b5% weight loss with spontaneous recovery at 14 dpi (Fig. 1A),
remained asymptomatic (Fig. 1B), and survived through the study peri-
od (Fig. 1C).
At euthanasia (12–14 dpi), H&E staining of the necropsied tissues of
these mice showed prominent acute inﬂammatory reactions with pre-
dominantly lymphocytic inﬁltrates. The most prominent inﬂammatory
changes were seen in the brain (cortical parenchymal and perivascular
lymphocytic inﬁltrates) (Fig. 4A to C), kidney (acute tubulitis and inter-
stitial inﬂammation) (Fig. 4D to F), and testis (necrotic and hemorrhagic
seminiferous tubules with marked lymphocytic inﬁltration in the pe-
rimeter of the tubules and the interstitium) (Fig. 5A to D). ZIKV-NS1
Fig. 2. Representative immunohistochemistry ﬁndings in the major organs of dexamethasone-immunosuppressed BALB/c mice with ZIKV inoculation and dexamethasone-
immunosuppressed mock-infected control mice. Sections of different tissues showing positive immunohistochemical staining for ZIKV-NS1 protein expression (mouse antiserum
against ZIKV-NS1 protein) in dexamethasone-immunosuppressed mice with ZIKV inoculation (A, C, E, G, I, K) and dexamethasone-immunosuppressed mice with mock infection (B, D,
F, H, J, L) (original magniﬁcation ×200 or ×400). (A) and (B) neurons in hippocampus (×200), (C) and (D) renal tubular cells (×400), (E) and (F) spermatocytes (×400), (G) and (H)
interstitial inﬂammatory cells in the lamina propria (×400), (I) and (J) salivary gland ductal epithelial cells (×400), and (K) and (L) splenic lymphocytes (×400). Arrows indicate cells
with ZIKV-NS1 protein expression stained in brown by DAB.
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nohistochemical staining of the testis/epididymis, ovary/uterus, kidney,
spleen, small intestine, pancreas, and salivary gland of the dexametha-
sone-immunosuppressedmicewith ZIKV inoculation at 12–14 dpi com-
paredwith 5 dpi. In contrast, no inﬂammatory reaction and viral protein
expression were seen in any organ of the control mice with ZIKV inocu-
lation alone (groups 3 and 4) or dexamethasone immunosuppression
alone (groups 5 and 6) (Fig. 5C and D). These ﬁndings conﬁrmed that
micewith ZIKV inoculation but nodexamethasone immunosuppression
were not susceptible to infection as previously reported, and that the
histological changes in themodel mice (groups 1 and 2)were unrelated
to dexamethasone-induced effects such as drug-induced testicular tox-
icity (Lazear et al., 2016; Dowall et al., 2016; Aliota et al., 2016; Rossi et
al., 2016; Khorsandi et al., 2013). The absence of inﬂammatory inﬁl-
trates in ZIKV-inoculated, dexamethasone-immunosuppressed mice
without dexamethasone withdrawal (group 9) supported the role of
the host immune response in eliciting the clinical and histological
changes in the ZIKV-inoculated mice with dexamethasone withdrawal
(groups 1 and 2).
To further conﬁrm the presence of inﬂammatory inﬁltrates and
characterize the cell types involved in the host immune response, we
stained the necropsied testis of the dexamethasone-immunosup-
pressed mice with ZIKV inoculation and those of the dexamethasone-
immunosuppressedmock-infected controlmicewith CD45 (pan-leuko-
cyte) and CD8 (cytotoxic T lymphocyte) antibodies. Corroborative to the
histological ﬁndings, only the testis of the dexamethasone-immunosup-
pressed mice with ZIKV inoculation, but not those of the control mice,
stained positive for CD45 (Fig. 5E and F) and CD8 antibodies (Fig. 5G
and H). These ﬁndings conﬁrmed the presence of inﬂammatory inﬁl-
trates and especially CD8+ T lymphocytes in the testis of the ZIKV-in-
fected mice.The dexamethasone-immunosuppressed mice with ZIKV inocula-
tion (groups 1 and 2) also had signiﬁcantly lower mean viral loads in
blood and most tissues at euthanasia at 12–14 dpi as compared with
those collected at 5 dpi (↓1–4 log10copies/106 β-actin at 12–14 dpi)
(Figs. 3A and B and S1A and B). At euthanasia (12–14 dpi), viral RNA
was still detectable in most tissues of the male mice (up to 3
log10copies/106 β-actin), but viremia was absent. The control mice
with ZIKV inoculation but no dexamethasone immunosuppression
had undetectable viral RNA in blood and most tissues, which was con-
sistent with previous reports (Lazear et al., 2016; Dowall et al., 2016;
Aliota et al., 2016; Rossi et al., 2016). Overall, these ﬁndings were sug-
gestive of multi-organ inﬂammation upon immune reconstitution
with partial viral clearance in the mice after withdrawal of dexametha-
sone immunosuppression.
3.3. Treatment with Recombinant Type I Interferons was Associated with
Better Clinical Outcome in the Mice
Wenext evaluated the effects of recombinant type I interferon treat-
ment in our mouse model.We usedmale mice as they had earlier onset
of weight loss and clinical symptoms requiring necropsy at 12 dpi. The
mice were treated with pegylated interferon-α2b (PegIntron®, Merck
& Co., Inc.,Whitehouse Station, NJ, USA) 1920 IU/dose every 96 h subcu-
taneously at 1 dpi, 5 dpi, and 9 dpi (group 10) or interferon-β1b
(Betaferon®, Bayer Schering Pharma AG, Berlin, Germany) 160,000 IU/-
dose every 48 h intraperitoneally at 1 dpi, 3 dpi, 5 dpi, 7 dpi, and 9 dpi
(group 11). As shown in Fig. 6A, the mice treated with pegylated inter-
feron-α2b (group 10) or interferon-β1b (group 11) had b10% weight
losswith spontaneous recovery at 14 dpi. Theweight loss of theuntreat-
ed group became signiﬁcantlymore than those of themice treated with
either interferon-α2 or interferon-β1b starting at 10 dpi (P b 0.05). All
AB
Fig. 3. Viral loads in the blood and major organs of dexamethasone-immunosuppressed BALB/c male and female mice with ZIKV inoculation. Mice ((A) male (5 dpi, n = 3 from two
independent experiments; 14 dpi, n = 6 from two independent experiments) and (B) female (5 dpi, n = 3 from two independent experiments; 14 dpi, n = 6 from two independent
experiments)) with dexamethasone immunosuppression had higher blood and tissue viral loads at 5 dpi while they were on dexamethasone than at euthanasia (12 dpi for male mice
and 14 dpi for female mice) after dexamethasone was stopped (10 dpi). ZIKV RNA copies in the blood and tissues of the mice were determined by real-time RT-PCR and normalized
by β-actin as described in the text. * denotes P-values of b0.05. *** denotes P-values b0.001. Error bars represent standard error of the mean.
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period (Fig. 6B and C). None of their tissues showed prominent inﬂam-
matory reactions in H&E staining at 5 dpi or 14 dpi. ZIKV-NS1 protein
expression was only rarely seen in the immunohistochemical staining
of the testis/epididymis, kidney, spleen, small intestine, lung, and pan-
creas collected at 5 dpi, and testis, epididymis, kidney, and spleen at
14 dpi. They had reduced mean viral loads in blood and all the tissues
(↓2–4 log10copies/106β-actin) as comparedwith those of the untreated
mice at 5 dpi and 14 dpi (Fig. 7A and B). The reductions were most sig-
niﬁcant in the tissues with high viral loads, such as the spleen, testis,
pancreas, and prostate (P b 0.05). Overall, these ﬁndings suggested
that early use of systemic recombinant type I interferons improvedthe clinical, histological, and virological parameters of mice with dis-
seminated ZIKV infection.
4. Discussion
The full spectrum of clinical manifestations and complications of
ZIKV infection remains incompletely understood as of today. The
previous assumption that ZIKV infection is an entirely self-limiting
disease without severe or long-lasting sequelae has been overturned by
the increasing recognition of congenitalmalformations, neurological com-
plications, immune-mediated thrombocytopenia, and even fatality in
some immunosuppressed patients (Pan American Health Organization/
Fig. 4. Representative histological ﬁndings in the brain and kidney of dexamethasone-immunosuppressed BALB/c mice with ZIKV inoculation and dexamethasone-immunosuppressed
mock-infected control mice. The brain and kidneys of all sacriﬁced mice were examined. Each organ was entirely embedded in one parafﬁn block, and one full-face parafﬁn section at
the maximum diameter of each organ was examined per block. Sections of the brain (12 dpi) of a dexamethasone-immunosuppressed mouse with ZIKV inoculation showing
(A) moderate degree of perivascular lymphocytic inﬁltrate and (B) marked lymphocytic inﬁltration in the cortical parenchyma (H&E, original magniﬁcation ×400). Section of the brain
(12 dpi) of dexamethasone-immunosuppressed mock-infected mouse showing normal architecture in the parenchyma (C) (H&E, original magniﬁcation ×400). Sections of the kidney
(12 dpi) showing (D) acute tubulitis with a large amount of inﬂammatory exudation in tubular lumens and (E) moderate degree of interstitial inﬂammation (H&E, original
magniﬁcation ×400). (F) Section of the kidney (12 dpi) of a dexamethasone-immunosuppressedmock-infectedmouse showing normal architecture (H&E, original magniﬁcation ×400).
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2016; Arzuza-Ortega et al., 2016; Duijster et al., 2016). Notably, patients
with severe non-pregnancy-related complications of ZIKV often deterio-
rated suddenly after an initially mild disease phase as the viral load
began to decrease (Cao-Lormeau et al., 2016; Mecharles et al., 2016;
Sarmiento-Ospina et al., 2016). This has led us to hypothesize that, like
many other ﬂavivirus infections, including yellow fever, dengue, and
West Nile virus infection, the host immune response may also play a
role in these ZIKV-associated complications, especially during the viral
clearance phase by the host immune system (Quaresma et al., 2013;
Screaton et al., 2015; Wang et al., 2003). In this study, we characterized
a novel and readily available mouse model for severe ZIKV infection
which attempts to provide an alternative venue for studying the host im-
mune response of and evaluating countermeasures for ZIKV infection. The
ﬁndings in our study have important implications on the pathogenesis,
potential complications, and treatment of ZIKV infection.
The dexamethasone-immunosuppressed mice with ZIKV inocula-
tion in our study developed disseminated infection with viremia and
multi-organ involvement, including the brain, urogenital tract, intes-
tine, liver, spleen, pancreas, heart, lung, and salivary gland as evident
by ZIKV-NS1 protein expression on immunohistochemical staining
and/or detectable viral load in these tissues. Immunohistochemistry
staining of the testis conﬁrmed the presence of inﬂammatory cell inﬁl-
trate (pan-leukocyte marker CD45+) with predominantly CD8+ T
lymphocytes. Clinically, the male mice developed earlier onset of dis-
ease than the female mice, with ≥10% weight loss and ≥1 clinical sign,
whichwarranted euthanasia at 12 dpi. Their weight loss, clinical scores,
and histological evidence of inﬂammatory reactions were most severe
soon after dexamethasone withdrawal, when viral loads had already
decreased by about 2–5 log10copies/106 β-actin. Overall, these ﬁndings
suggested that, like the other related ﬂaviviruses, the host immune re-
sponsemight have led tomarked clinical deterioration in the face of dis-
seminated ZIKV infection at the time when immune-mediated
clearance of the virus began. Our ﬁndings provided an additional expla-
nation for the pathogenesis of fatal ZIKV infection, which has been pro-
posed to be related to uncontrolled virus dissemination in previouslydescribedmousemodels utilizing types I/II interferon-signaling-/recep-
tor-deﬁcient mice that were unable to mount a robust host innate im-
mune response.
Our mouse model is also useful for studying ZIKV's tissue tropism
and potential complications of severe ZIKV infection. In addition to the
reported ﬁndings of detectable virus particles and/or RNA in the brain,
spinal cord, kidney, spleen, liver, testis, ovary, heart, lung, muscle, and
blood of types I/II interferon-signaling-/receptor-deﬁcient mice with
ZIKV infection, our study identiﬁed intestine, pancreas, and salivary
gland as other possible tissues and anatomical sites for virus infection
(Dick, 1952; Lazear et al., 2016; Dowall et al., 2016; Aliota et al., 2016;
Rossi et al., 2016). This tissue tropism of ZIKV in our mouse model con-
curs with the in-vitro observation that ZIKV efﬁciently replicates in di-
verse cell types of neuronal, testicular, prostatic, renal, intestinal,
hepatic, and placental origin (Chan et al., 2016b; Brault et al., 2016;
Hughes et al., 2016). Such degree of virus dissemination and multi-
organ involvement is also compatible with the clinical ﬁndings in pa-
tients with severe and/or fatal ZIKV infection, in whom viral particles
and/or RNAwere detected inmultiple organs at post-mortem examina-
tion (Pan American Health Organization/World Health Oganization
(PAHO/WHO), 2015; Sarmiento-Ospina et al., 2016; Arzuza-Ortega et
al., 2016). While inﬂammatory neurological complications, such as
Guillain-Barré syndrome, meningoencephalitis, and myelitis, have
been recently reported in patients with ZIKV infection, inﬂammatory
disorders of the other non-neuronal tissues were not well recognized
(Cao-Lormeau et al., 2016; Carteaux et al., 2016; Mecharles et al.,
2016). Our ﬁndings showed that inﬂammation could be observed in
multiple organs including the testis, kidney, spleen, liver, intestine, pan-
creas, lung, and salivary gland outside the nervous system.
Among these non-neuronal tissues, the inﬂammatory reactions
were most prominent in the testis of our model mice. Some patients
with ZIKV infection reported hematospermia, pelvic pain, and dysuria
with detectable viral particles and/or RNA in their semen (Chan et al.,
2016a; Musso et al., 2015a; Foy et al., 2011). Histological evidence of
orchitis has not been reported due to the difﬁculty in obtaining the pa-
tients' testicular tissues for histological examination. Previous mouse
Fig. 5. Representative histological ﬁndings and immunohistochemistry staining of the testis of dexamethasone-immunosuppressed BALB/c mice with ZIKV inoculation and
dexamethasone-immunosuppressed mock-infected control mice. Sections (H&E) of the testis of a dexamethasone-immunosuppressed mouse with ZIKV inoculation (A and C) and
mock infection (B and D). (A, original magniﬁcation ×100) and (C, original magniﬁcation ×400): necrotic and hemorrhagic seminiferous tubules associated with marked lymphocytic
inﬁltration (arrows) in the perimeter of the tubules and the interstitium. (B, original magniﬁcation ×100) and (D, original magniﬁcation ×400): normal architecture consisting of
seminiferous tubules with layers of cells in normal maturation stages. Immunohistochemistry staining of CD45 (E and F) and CD8 (G and H) antigens showing CD45+ and CD8+ cells
(arrows) in the testis of dexamethasone-immunosuppressed mice with ZIKV inoculation (E and G) but not the dexamethasone-immunosuppressed mice with mock infection (F and
H) (E to H, original magniﬁcation ×400).
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ceptor-deﬁcient mice have also showed that viral particles and RNA
could be detected in the mice's testes, but histological analysis were
not reported (Lazear et al., 2016). The markedly necrotic and hemor-
rhagic seminiferous tubules observed in our mice are highly alarmingas orchitis may have long-term effects on fertility. These changes were
not accountable by dexamethasone-induced testicular toxicity, as they
were morphologically different from the latter, and were not present
in any of the testes of the control mice with dexamethasone treatment
and mock infection (Khorsandi et al., 2013). During revision of this
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Fig. 6. Comparison of the clinical ﬁndings of the dexamethasone-immunosuppressed BALB/c mice with ZIKV inoculation with and without recombinant type I interferon treatment. (A)
Body weights, (B) clinical scores, and (C) survival times and rates. Body weights of the mice were monitored for 14 days (survival mice) or until euthanasia. The mice were treated with
pegylated interferon-α2b (PegIntron®, Merck & Co., Inc., Whitehouse Station, NJ, USA) 1920 IU/dose every 96 h subcutaneously at 1 dpi, 5 dpi, and 9 dpi or interferon-β1b (Betaferon®,
Bayer Schering Pharma AG, Berlin, Germany) 160,000 IU/dose every 48 h intraperitoneally at 1 dpi, 3 dpi, 5 dpi, 7 dpi, and 9 dpi. No interferon treatment group (n= 6), interferon-α2b
treatment group (n = 8), and interferon-β1b treatment group (n = 8). Results were combined from two independent experiments. P-values b0.05 are indicated by (no interferon
treatment versus interferon-α2b treatment) and * (no interferon treatment versus interferon-β1b treatment). Abbreviation: IFN, interferon. Clinical scores: normal = 0; rufﬂed fur =
2; lethargy, pinched, hunched, wasp waisted = 3; labored breathing, rapid breathing, inactive, neurological = 5; and immobile = 10.
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ed with anti-Ifna1 blocking monoclonal antibody and inoculated with
ZIKV (Govero et al., 2016). Clinical studies to conﬁrm the presence of
orchitis and to assess the fertility of convalescent male patients should
be conducted to ascertain the long-term consequences of ZIKV infection
regarding reproductive and hormonal derangements. Inﬂammation of
other organs, such as acute tubulitis, interstitial nephritis, sialadenitis,
hepatitis, enteritis, and acute pancreatitis have been reported in pa-
tients with ZIKV or other ﬂavivirus infections (Chan et al., 2016a;
Sarmiento-Ospina et al., 2016; Arzuza-Ortega et al., 2016; Duijster et
al., 2016; Bonaldo et al., 2016; Gourinat et al., 2015; Musso et al.,
2015b; Mercado et al., 2016; Bhagat et al., 2012; Torres et al., 2000;
Macnamara, 1954; Chatterjee et al., 2014). These potential complica-
tions may be increasingly recognized as the ZIKV epidemic continues
to expand into developed countries with a large ageing and immuno-
suppressed population.
Finally, our mouse model also provided a novel avenue for the eval-
uation of anti-ZIKV treatment. Type I interferons have broad-spectrum
antiviral activities including those against ZIKV, but type I interferon-
signaling-/receptor-deﬁcient mice were not suitable for evaluation of
the effects of recombinant type I interferons. We therefore evaluated
the antiviral effects of two commercially available preparations of re-
combinant type I interferons in this new mouse model (Hamel et al.,
2015; Zumla et al., 2016; Chan et al., 2013; Chan et al., 2015b). We
showed that the early use of either drug was associated with improved
clinical outcome with no fatality (100% fatality in untreated mice),
markedly decreased inﬂammatory response after dexamethasonewith-
drawal, and reduced viral loads in various tissues of the mice ascompared to those of the untreated mice. The viral load reductions
were especially signiﬁcant in the early phase of the disease (5 dpi),
when the mice were on dexamethasone. These ﬁndings suggested
that the early use of recombinant interferons might help to control
viral replication during the initial phase of infection, and prevent the
subsequent development of severe complications related to an exagger-
ated immune response in the presence of high viral loads as seen in the
untreated mice. It is important to further conﬁrm these results in our
mouse model using different ZIKV strains and in clinical trials because
ZIKV antagonizes mouse STAT2 less efﬁciently than human STAT2, and
thus may be more susceptible to type I interferons in mice (Grant et
al., 2016).Whilemost patientswithmild ZIKV infectionmay not require
systemic interferon treatment, clinical trials should be considered to
evaluate the beneﬁts of the early use of interferon treatment in patients
at risk of developing severe ZIKV-associated complications, such as
those with underlying comorbidities (Sarmiento-Ospina et al., 2016).
The increased risk of fetal loss and low birth weight associated with in-
terferon therapy in the ﬁrst trimester of pregnancy may be outweighed
by the risk of congenital malformations due to ZIKV infection. The opti-
mal timing of treatment commencement should be further investigated
as late commencement of interferon treatment may be useless or dele-
terious and should be avoided (Solomon et al., 2003).
In summary, this novel mouse model is useful for investigating host
immune response-associated damage of and evaluating countermea-
sures for ZIKV infection. Inﬂammation of different visceral organs may
be important complications of ZIKV that should be further studied in in-
fected humans. Long-termmonitoring of the testicular function of ZIKV-
infected male patients should be considered. Clinical trials should be
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Fig. 7.Viral loads in the blood andmajor organs of dexamethasone-immunosuppressed BALB/cmice with ZIKV inoculationwith orwithout recombinant type I interferon treatment.Male
mice with interferon-α2b or -β1b treatment had reduced ZIKV blood and tissue viral loads as compared to untreated mice at (A) 5 dpi (n = 3 per group from two independent
experiments) and (B) 14 dpi (n = 6–8 per group from two independent experiments). ZIKV RNA copies in the blood and tissues of the mice were determined by real-time RT-PCR
and normalized by β-actin as described in the text. * denotes P-values of b0.05. Error bars represent standard error of the mean.
121J.F.-W. Chan et al. / EBioMedicine 14 (2016) 112–122considered for evaluating the effects of recombinant interferon treat-
ments in patients at high risk for ZIKV-associated complications when
the potential beneﬁts may outweight the side effects of treatment.
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